新型冠状病毒感染：甲状腺疾病的新挑战
收稿日期: 2021-11-02
网络出版日期: 2023-02-27
基金资助
江苏省中医药领军人才(SLJ0209);重大疑难疾病中西医临床协作试点项目(2018)
Novel coronavirus infection: a new challenge for the management of thyroid disease
相萍萍, 刘超 . 新型冠状病毒感染：甲状腺疾病的新挑战[J]. 内科理论与实践, 2022 , 17(06) : 486 -490 . DOI: 10.16138/j.1673-6087.2022.06.013
| [1] | World Health Organization. Coronavirus disease (COVID-2019) situation reports[EB/OL]. 2022. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. |
| [2] | Temgoua MN, Endomba FT, Nkeck JR, et al. Coronavirus disease 2019(COVID-19) as a multi-systemic disease and its impact in low- and middle-income countries (LMICs)[J]. SN Compr Clin Med, 2020, 2(9): 1377-1387. |
| [3] | Pal R, Banerjee M. COVID-19 and the endocrine system: exploring the unexplored[J]. J Endocrinol Invest, 2020, 43(7): 1027-1031. |
| [4] | Rotondi M, Coperchini F, Ricci G, et al. Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis[J]. J Endocrinol Invest, 2021, 44(5): 1085-1090. |
| [5] | Gorini F, Bianchi F, Iervasi G. COVID-19 and thyroid: progress and prospects[J]. Int J Environ Res Public Health, 2020, 17(18): 6630. |
| [6] | 孙申, 卫兰, 张京, 等. 严重急性呼吸综合征患者甲状腺的病理学改变[J]. 中华医学杂志, 2005, 85(10): 667-670. |
| [7] | Bradley BT, Maioli H, Johnston R, et al. Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State[J]. Lancet, 2020, 396(10247): 320-332. |
| [8] | Barton LM, Duval EJ, Stroberg E, et al. COVID-19 autopsies, Oklahoma, USA[J]. Am J Clin Pathol, 2020, 153(6): 725-733. |
| [9] | 姚小红, 李廷源, 何志承, 等. 新型冠状病毒肺炎(COVID-19)三例遗体多部位穿刺组织病理学研究[J]. 中华病理学杂志, 2020, 49(5): 411-417. |
| [10] | Brancatella A, Ricci D, Viola N, et al. Subacute thyroiditis after SARS-COV-2 infection[J]. J Clin Endocrinol Metab, 2020, 105(7): dgaa276. |
| [11] | Inaba H, Aizawa T. Coronavirus disease 2019 and the thyroid[J]. Front Endocrinol (Lausanne), 2021, 12: 708333. |
| [12] | Mattar SAM, Koh SJQ, Rama Chandran S, et al. Sub-acute thyroiditis associated with COVID-19[J]. BMJ Case Rep, 2020, 13(8): e237336. |
| [13] | Muller I, Cannavaro D, Dazzi D, et al. SARS-CoV-2-related atypical thyroiditis[J]. Lancet Diabetes Endocrinol, 2020, 8(9): 739-741. |
| [14] | Ruggeri RM, Campennì A, Siracusa M, et al. Subacute thyroiditis in a patient infected with SARS-COV-2: an endocrine complication linked to the COVID-19 pandemic[J]. Hormones (Athens), 2021, 20(1): 219-221. |
| [15] | Mizuno S, Inaba H, Kobayashi KI, et al. A case of postpartum thyroiditis following SARS-CoV-2 infection[J]. Endocr J, 2021, 68(3): 371-374. |
| [16] | Mateu-Salat M, Urgell E, Chico A. SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves’ disease after COVID-19[J]. J Endocrinol Invest, 2020, 43(10):1527-1528. |
| [17] | Jiménez-Blanco S, Pla-Peris B, Marazuela M. COVID-19: a cause of recurrent Graves’ hyperthyroidism?[J]. J Endocrinol Invest, 2021, 44(2): 387-388. |
| [18] | Pastor S, Molina á Sr, De Celis E. Thyrotoxic crisis and COVID-19 infection[J]. Cureus, 2020, 12(11):e11305. |
| [19] | Tee LY, Harjanto S, Rosario BH. COVID-19 complicated by Hashimoto’s thyroiditis[J]. Singapore Med J, 2021, 62(5):265. |
| [20] | Lui DTW, Lee CH, Chow WS, et al. Thyroid dysfunction in relation to immune profile, disease status, and outcome in 191 patients with COVID-19[J]. J Clin Endocrinol Metab, 2021, 106(2): e926-e935. |
| [21] | Boelaert K, Visser WE, Taylor PN, et al. Endocrinology in the time of COVID-19[J]. Eur J Endocrinol, 2020, 183(1): G33-G39. |
| [22] | Zou R, Wu C, Zhang S, et al. Euthyroid sick syndrome in patients with COVID-19[J]. Front Endocrinol (Lausanne), 2020, 11: 566439. |
| [23] | Gao W, Guo W, Guo Y, et al. Thyroid hormone concentrations in severely or critically ill patients with COVID-19[J]. J Endocrinol Invest, 2021, 44(5):1031-1040. |
| [24] | Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019[J]. BMJ, 2020, 368: m1091. |
| [25] | Chen M, Zhou W, Xu W. Thyroid function analysis in 50 patients with COVID-19[J]. Thyroid, 2021, 31(1): 8-11. |
| [26] | Moore JB, June CH. Cytokine release syndrome in severe COVID-19[J]. Science, 2020, 368(6490): 473-474. |
| [27] | Tang Y, Liu J, Zhang D, et al. Cytokine storm in COVID-19[J]. Front Immunol, 2020, 11: 1708. |
| [28] | De Biasi S, Meschiari M, Gibellini L, et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia[J]. Nat Commun, 2020, 11(1): 3434. |
| [29] | Ruggeri RM, Giuffrida G, Campennì A. Autoimmune endocrine diseases[J]. Minerva Endocrinol, 2018, 43(3): 305-322. |
| [30] | Nanba T, Watanabe M, Inoue N, et al. Increases of the Th1/Th2 cell ratio in severe Hashimoto’s disease and in the proportion of Th17 cells in intractable Graves’ disease[J]. Thyroid, 2009, 19(5): 495-501. |
| [31] | Shi Y, Wang H, Su Z, et al. Differentiation imbalance of Th1/Th17 in peripheral blood mononuclear cells might contribute to pathogenesis of Hashimoto’s thyroiditis[J]. Scand J Immunol, 2010, 72(3): 250-255. |
| [32] | Figueroa-Vega N, Alfonso-Pérez M, Benedicto I, et al. Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto’s thyroiditis[J]. J Clin Endocrinol Metab, 2010, 95(2): 953-962. |
| [33] | Li Q, Wang B, Mu K, et al. The pathogenesis of thyroid autoimmune diseases: new T lymphocytes-cytokines circuits beyond the Th1-Th2 paradigm[J]. J Cell Physiol, 2019, 234(3): 2204-2216. |
| [34] | Lania A, Sandri MT, Cellini M, et al. Thyrotoxicosis in patients with COVID-19[J]. Eur J Endocrinol, 2020, 183(4): 381-387. |
| [35] | Campi I, Bulgarelli I, Dubini A, et al. The spectrum of thyroid function tests during hospitalization for SARS COV-2 infection[J]. Eur J Endocrinol, 2021, 184(5): 699-709. |
| [36] | Wang W, Zhang W, Zhang J, et al. Distribution of HLA allele frequencies in 82 Chinese individuals with coronavirus disease-2019(COVID-19)[J]. HLA, 2020, 96(2): 194-196. |
| [37] | Novelli A, Andreani M, Biancolella M, et al. HLA allele frequencies and susceptibility to COVID-19 in a group of 99 Italian patients[J]. HLA, 2020, 96(5): 610-614. |
| [38] | Ohsako N, Tamai H, Sudo T, et al. Clinical characteristics of subacute thyroiditis classified according to human leukocyte antigen typing[J]. J Clin Endocrinol Metab, 1995, 80(12):3653-3656. |
| [39] | Grumet FC, Payne RO, Konishi J, et al. HL-A antigens as markers for disease susceptibility and autoimmunity in Graves’ disease[J]. J Clin Endocrinol Metab, 1974, 39(6): 1115-1119. |
| [40] | Tomer Y, Davies TF. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function[J]. Endocr Rev, 2003, 24(5): 694-717. |
| [41] | Lazartigues E, Qadir MMF, Mauvais-Jarvis F. Endocrine significance of SARS-CoV-2’s reliance on ACE2[J]. Endocrinology. 2020, 161(9): bqaa108. |
| [42] | van Gerwen M, Alsen M, Little C, et al. Outcomes of patients with hypothyroidism and COVID-19[J]. Front Endocrinol (Lausanne), 2020, 11: 565. |
| [43] | Zhang Y, Lin F, Tu W, et al. Thyroid dysfunction may be associated with poor outcomes in patients with COVID-19[J]. Mol Cell Endocrinol, 2021, 521: 111097. |
| [44] | Hariyanto TI, Kurniawan A. Thyroid disease is associated with severe coronavirus disease 2019(COVID-19) infection[J]. Diabetes Metab Syndr, 2020, 14(5):1429-1430. |
| [45] | Weisberg E, Parent A, Yang PL, et al. Repurposing of kinase inhibitors for treatment of COVID-19[J]. Pharm Res, 2020, 37(9):167. |
| [46] | Prescott HC, Rice TW. Corticosteroids in COVID-19 ARDS: evidence and hope during the pandemic[J]. JAMA, 2020, 324(13): 1292-1295. |
| [47] | Elston MS, Conaglen HM, Hughes C, et al. Duration of cortisol suppression following a single dose of dexamethasone in healthy volunteers: a randomised double-blind placebo-controlled trial[J]. Anaesth Intensive Care, 2013, 41(5): 596-601. |
| [48] | Alkemade A, Unmehopa UA, Wiersinga WM, et al. Glucocorticoids decrease thyrotropin-releasing hormone messenger ribonucleic acid expression in the paraventricular nucleus of the human hypothalamus[J]. J Clin Endocrinol Metab, 2005, 90(1): 323-327. |
| [49] | Schatz DL, Sheppard RH, Steiner G, et al. Influence of heparin on serum free thyroxine[J]. J Clin Endocrinol Metab, 1969, 29(8): 1015-1022. |
| [50] | Mendel CM, Frost PH, Cavalieri RR. Effect of free fatty acids on the concentration of free thyroxine in human serum: the role of albumin[J]. J Clin Endocrinol Metab, 1986, 63(6): 1394-1399. |
| [51] | Mendel CM, Frost PH, Kunitake ST, et al. Mechanism of the heparin-induced increase in the concentration of free thyroxine in plasma[J]. J Clin Endocrinol Metab, 1987, 65(6):1259-1264. |
| [52] | Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP, et al. Two cases of Graves’ disease following SARS-CoV-2 vaccination[J]. Thyroid, 2021, 31(9): 1436-1439. |
| [53] | Iremli BG, ?endur SN, ünlütürk U. Three cases of subacute thyroiditis following SARS-CoV-2 vaccine[J]. J Clin Endocrinol Metab, 2021, 106(9): 2600-2605. |
| [54] | Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens[J]. Front Immunol, 2020, 11:617089. |
/
| 〈 |
|
〉 |
